Peptide TherapeuticsPeer Reviewed
EOTP-2025-ST-0028.R1Insights and trends in development of TEAD-YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025).
Authors (5)
Te FanDepartment of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China.
Zhong YuDepartment of Intellectual Property and Intelligence, Zhuhai Hengqin Haomai Technology Co, LTD, Zhuhai, Guangdong, P.R. China.
Aiping XiaoDepartment of Pharmacy, Tangdu Hospital, Fourth Military Medical University，Xi'an，Shaanxi, P.R. China.
Yan ZhangDepartment of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China.
Expert opinion on therapeutic patents
Unknown
Published
Oct 13, 2025
Abstract
Abstract not available - data parsing issue resolved
Keywords
Hippo signaling pathwayTEAD-YAP/TAZacyclic moietiescyclic systemspatent review
Article Metrics
Sourcepubmed
Related Research
Explore more articles in this research category to discover related studies and findings.